Toxicological studies on a new macrolide antibiotic, midecamycin acetate (miokamycin). Part III-4. Chronic toxicity in beagle dogs: 26-week-treatment in male dogs.
Miokamycin (MOM) is a derivative of midecamycin, a macrolide antibiotic isolated from a culture broth of Streptomyces mycarofaciens. The objective of this study was to determine the chronic toxicity of MOM in male Beagle dogs after repeated oral administration of MOM, non-crystalline solid, for 26 weeks at b.i.d. dosage of 200, 400, 800 and 1,200 mg/kg/day. It is concluded that MOM, non-crystalline solid, did not show any toxic effects in this chronic toxicity study. Therefore, the maximum non-toxic dose is presumed to be 1,200 mg/kg/day or more in male Beagle dogs administered orally at b.i.d. for 26 weeks.
D000818:Animals; D004285:Dogs; D007684:Kidney Tubules / Q000648:ultrastructure; D007933:Leucomycins / Q000633:toxicity*; D008297:Male; D015644:Miocamycin; D008930:Mitochondria, Liver / Q000648:ultrastructure; D008933:Mitochondrial Swelling / Q000187:drug effects; D013223:Statistics as Topic
D007933:Leucomycins; D015644:Miocamycin